Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 125 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt), fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - salmeterol 50 ug - advair diskus is indicated for the treatment of asthma in patients aged 4 years and older. long-acting beta2 -adrenergic agonists (labas), such as salmeterol, one of the active ingredients in advair diskus, increase the risk of asthma-related death. available data from controlled clinical trials suggest that labas increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see warnings and precautions (5.1)] . therefore, when treating patients with asthma, physicians should only prescribe advair diskus for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid, or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a laba. once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue advair diskus) if possible without loss of asthma control and maintain the patient on a long-term asthma control medication, s

United States - English - NLM (National Library of Medicine)

rebel distributors corp - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt), fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - salmeterol xinafoate 50 ug - advair diskus is indicated for the treatment of asthma in patients aged 4 years and older. long-acting beta2 -adrenergic agonists (labas), such as salmeterol, one of the active ingredients in advair diskus, increase the risk of asthma-related death. available data from controlled clinical trials suggest that labas increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see warnings and precautions (5.1)] . therefore, when treating patients with asthma, physicians should only prescribe advair diskus for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid, or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a laba. once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue advair diskus) if possible without loss of asthma control and maintain the patient on a long-term asthma control medication, s

United States - English - NLM (National Library of Medicine)

dispensing solutions inc. - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt), fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - salmeterol xinafoate 50 ug - advair diskus is indicated for the long-term, twice-daily, maintenance treatment of asthma in patients aged 4 years and older. long-acting beta2 -adrenergic agonists, such as salmeterol, one of the active ingredients in advair diskus, may increase the risk of asthma-related death [see warnings and precautions (5.1)] . therefore, when treating patients with asthma, physicians should only prescribe advair diskus for patients not adequately controlled on other asthma-controller medications (e.g., low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with 2 maintenance therapies. important limitations of use: - advair diskus is not indicated for the relief of acute bronchospasm. - advair diskus is not indicated in patients whose asthma can be successfully managed by inhaled corticosteroids along with occasional use of inhaled, short-acting beta2 -agonists. advair diskus 250/50 is indicated for the twice-daily maintenance treatment of airflow obstruction in

United States - English - NLM (National Library of Medicine)

rebel distributors corp. - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt), fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - salmeterol xinafoate 50 ug - advair diskus is indicated for the treatment of asthma in patients aged 4 years and older. long-acting beta2 -adrenergic agonists (labas), such as salmeterol, one of the active ingredients in advair diskus, increase the risk of asthma-related death. available data from controlled clinical trials suggest that labas increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see warnings and precautions (5.1)] .therefore, when treating patients with asthma, physicians should only prescribe advair diskus for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid, or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a laba. once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue advair diskus) if possible without loss of asthma control and maintain the patient on a long-term asthma control medication, su

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt), fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - salmeterol xinafoate 50 ug - advair diskus is indicated for the treatment of asthma in patients aged 4 years and older. long-acting beta2 -adrenergic agonists (labas), such as salmeterol, one of the active ingredients in advair diskus, increase the risk of asthma-related death. available data from controlled clinical trials suggest that labas increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see warnings and precautions (5.1)] .therefore, when treating patients with asthma, physicians should only prescribe advair diskus for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid, or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a laba. once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue advair diskus) if possible without loss of asthma control and maintain the patient on a long-term asthma control medication, s

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - salmeterol 50 ug - serevent diskus is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with a long-term asthma control medication, such as an inhaled corticosteroid, in patients aged 4 years and older with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma. laba, such as salmeterol, the active ingredient in serevent diskus, increase the risk of asthma-related death [see warnings and precautions (5.1)] . use of serevent diskus for the treatment of asthma without concomitant use of a long-term asthma control medication, such as an inhaled corticosteroid, is contraindicated [see contraindications (4)] . use serevent diskus only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid. once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue sere

United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - salmeterol 50 ug - serevent diskus is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with an ics in patients aged 4 years and older with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma. laba, such as salmeterol, the active ingredient in serevent diskus, as monotherapy (without ics) increase the risk of asthma-related death [see warnings and precautions (5.1)] . use of serevent diskus for the treatment of asthma without concomitant use of an ics is contraindicated [see contraindications (4)] . use serevent diskus only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on an ics. do not use serevent diskus for patients whose asthma is adequately controlled on low- or medium-dose ics. pediatric and adolescent patients available data from controlled clinical trials suggest that laba as monotherapy increase the risk of asthma-related hospitalization in pediatric and adolescent pati

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg; fluticasone propionate, quantity: 0.25 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include ? patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? patients who are symptomatic on current inhaled corticosteroid therapy for the symptomatic treatment of patients with severe copd (fev1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. fluticasone salmeterol cip haler 250/50 is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg; fluticasone propionate, quantity: 0.25 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include ? patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? patients who are symptomatic on current inhaled corticosteroid therapy for the symptomatic treatment of patients with severe copd (fev1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. fluticasone salmeterol multi haler 250/50 is not indicated for the initiation of bronchodilator therapy in copd